These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 12969434)

  • 1. Doxorubicin-induced cardiac mitochondrionopathy.
    Wallace KB
    Pharmacol Toxicol; 2003 Sep; 93(3):105-15. PubMed ID: 12969434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis.
    Wallace KB
    Cardiovasc Toxicol; 2007; 7(2):101-7. PubMed ID: 17652813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beneficial role of exercise in mitigating doxorubicin-induced Mitochondrionopathy.
    Marques-Aleixo I; Santos-Alves E; Oliveira PJ; Moreira PI; Magalhães J; Ascensão A
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):189-199. PubMed ID: 29408395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin-induced chronic dilated cardiomyopathy-the apoptosis hypothesis revisited.
    Kankeu C; Clarke K; Passante E; Huber HJ
    J Mol Med (Berl); 2017 Mar; 95(3):239-248. PubMed ID: 27933370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol.
    Pereira GC; Silva AM; Diogo CV; Carvalho FS; Monteiro P; Oliveira PJ
    Curr Pharm Des; 2011; 17(20):2113-29. PubMed ID: 21718248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripartum cardiomyopathy occurring in a patient previously treated with doxorubicin.
    Katz A; Goldenberg I; Maoz C; Thaler M; Grossman E; Rosenthal T
    Am J Med Sci; 1997 Dec; 314(6):399-400. PubMed ID: 9413345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular function in patients with toxic cardiomyopathy and with idiopathic dilated cardiomyopathy treated with Doxorubicin.
    Katamadze NA; Lartsuliani KP; Kiknadze MP
    Georgian Med News; 2009 Jan; (166):43-8. PubMed ID: 19202217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.
    Wallace KB; Sardão VA; Oliveira PJ
    Circ Res; 2020 Mar; 126(7):926-941. PubMed ID: 32213135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondria-specific nano-emulsified therapy for myocardial protection against doxorubicin-induced cardiotoxicity.
    Faulk A; Weissig V; Elbayoumi T
    Methods Mol Biol; 2013; 991():99-112. PubMed ID: 23546663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin.
    Tokarska-Schlattner M; Wallimann T; Schlattner U
    C R Biol; 2006 Sep; 329(9):657-68. PubMed ID: 16945832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin induces senescence and impairs function of human cardiac progenitor cells.
    Piegari E; De Angelis A; Cappetta D; Russo R; Esposito G; Costantino S; Graiani G; Frati C; Prezioso L; Berrino L; Urbanek K; Quaini F; Rossi F
    Basic Res Cardiol; 2013 Mar; 108(2):334. PubMed ID: 23411815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dilated cardiomyopathy in a pregnant woman after doxorubicin and radiotherapy for Hodgkin's disease: a case report.
    Hadar A; Sheiner E; Press F; Katz A; Katz M
    J Reprod Med; 2004 May; 49(5):401-3. PubMed ID: 15214719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment.
    Berthiaume JM; Wallace KB
    Cardiovasc Toxicol; 2007; 7(3):178-91. PubMed ID: 17901561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy.
    Carvalho RA; Sousa RP; Cadete VJ; Lopaschuk GD; Palmeira CM; Bjork JA; Wallace KB
    Toxicology; 2010 Apr; 270(2-3):92-8. PubMed ID: 20132857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complications of chemotherapy, a basic science update.
    Mazevet M; Moulin M; Llach-Martinez A; Chargari C; Deutsch E; Gomez AM; Morel E
    Presse Med; 2013 Sep; 42(9 Pt 2):e352-61. PubMed ID: 23972551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Biophysical Systems Approach to Identifying the Pathways of Acute and Chronic Doxorubicin Mitochondrial Cardiotoxicity.
    de Oliveira BL; Niederer S
    PLoS Comput Biol; 2016 Nov; 12(11):e1005214. PubMed ID: 27870850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrophic nerve fibers in regions of reduced MIBG uptake in doxorubicin cardiomyopathy.
    Takano H; Ozawa H; Kobayashi I; Hamaoka S; Nakajima A; Nakamura T; Naitoh A; Koizumi K; Tamura K
    J Nucl Med; 1995 Nov; 36(11):2060-1. PubMed ID: 7472599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The feature of cardial remodeling process at Doxorubicin chemotherapy and idiopathic dilatative cardiomyopathy].
    Katamadze NA; Lartsuliani KP; Begishvili NN; Dundua KhV; Kiknadze MP
    Georgian Med News; 2006 Jan; (130):61-4. PubMed ID: 16510915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy.
    Santos DL; Moreno AJ; Leino RL; Froberg MK; Wallace KB
    Toxicol Appl Pharmacol; 2002 Dec; 185(3):218-27. PubMed ID: 12498738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotective effect of grape-seed proanthocyanidins on doxorubicin-induced cardiac toxicity in rats.
    Ammar el-SM; Said SA; El-Damarawy SL; Suddek GM
    Pharm Biol; 2013 Mar; 51(3):339-44. PubMed ID: 23134235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.